Hello
Thank you for sharing your concerns about your father’s CML (BCR-ABL) status. While the increase from 0.3% to 1.3% could be due to lab variability as suggested by the doctor, it is important to monitor this trend closely. CML management relies heavily on achieving and maintaining molecular response, and any upward trend in BCR-ABL levels should be evaluated carefully to rule out resistance or suboptimal treatment response.
Since your father has already switched therapies due to tolerability issues, a detailed review of his case—including possible mutation testing or dose adjustments—may be necessary. I strongly recommend a **consultation with a CML specialist** to ensure the best course of action.
For further discussion or to schedule an appointment, you can reach me on WhatsApp at **Eight Zero Zero Nine Eight Two One Three Three Two**. Early intervention can make a significant difference in long-term outcomes.
Answered2025-04-10 10:16:44
Let others know if this answer was helpful